当前位置: X-MOL 学术J. Cell. Mol. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
IGFBP-4 enhances VEGF-induced angiogenesis in a mouse model of myocardial infarction.
Journal of Cellular and Molecular Medicine ( IF 4.3 ) Pub Date : 2020-06-28 , DOI: 10.1111/jcmm.15516
Da Wo 1 , Jinxiao Chen 1 , Qiongyu Li 2 , En Ma 3 , Hongwei Yan 3 , Jun Peng 2 , Weidong Zhu 3 , Yong Fang 1 , Dan-Ni Ren 2
Affiliation  

Vascular endothelial growth factor (VEGF) is a well‐known angiogenic factor, however its ability in promoting therapeutic angiogenesis following myocardial infarction (MI) is limited. Here, we aimed to investigate whether dual treatment with insulin‐like growth factor binding protein‐4 (IGFBP‐4), an agent that protects against early oxidative damage, can be effective in enhancing the therapeutic effect of VEGF following MI. Combined treatment with IGFBP‐4 enhanced VEGF‐induced angiogenesis and prevented cell damage via enhancing the expression of a key angiogenic factor angiopoietin‐1. Dual treatment with the two agents synergistically decreased cardiac fibrosis markers collagen‐I and collagen‐III following MI. Importantly, while the protective action of IGFBP‐4 occurs at an early stage of ischemic injury, the action of VEGF occurs at a later stage, at the onset angiogenesis. Our findings demonstrate that VEGF treatment alone is often not enough to protect against oxidative stress and promote post‐ischemic angiogenesis, whereas the combined treatment with IGFBP4 and VEGF can utilize the dual roles of these agents to effectively protect against ischemic and oxidative injury, and promote angiogenesis. These findings provide important insights into the roles of these agents in the clinical setting, and suggest new strategies in the treatment of ischemic heart disease.

中文翻译:

IGFBP-4 在心肌梗塞小鼠模型中增强 VEGF 诱导的血管生成。

血管内皮生长因子(VEGF)是一种众所周知的血管生成因子,但其在心肌梗死(MI)后促进治疗性血管生成的能力有限。在这里,我们的目的是研究胰岛素样生长因子结合蛋白 4(IGFBP-4)(一种防止早期氧化损伤的药物)双重治疗是否可以有效增强 MI 后 VEGF 的治疗效果。与 IGFBP-4 联合治疗通过增强关键血管生成因子血管生成素-1 的表达增强 VEGF 诱导的血管生成并防止细胞损伤。两种药物的双重治疗可协同降低 MI 后心脏纤维化标志物胶原蛋白-I 和胶原蛋白-III。重要的是,虽然 IGFBP-4 的保护作用发生在缺血性损伤的早期阶段,VEGF 的作用发生在较晚的阶段,即血管生成开始时。我们的研究结果表明,单独的 VEGF 治疗通常不足以防止氧化应激和促进缺血后血管生成,而 IGFBP4 和 VEGF 的联合治疗可以利用这些药物的双重作用有效地防止缺血和氧化损伤,并促进血管生成。这些发现为了解这些药物在临床环境中的作用提供了重要见解,并提出了治疗缺血性心脏病的新策略。而IGFBP4和VEGF的联合治疗可以利用这些药物的双重作用,有效地防止缺血和氧化损伤,促进血管生成。这些发现为了解这些药物在临床环境中的作用提供了重要见解,并提出了治疗缺血性心脏病的新策略。而IGFBP4和VEGF的联合治疗可以利用这些药物的双重作用,有效地防止缺血和氧化损伤,促进血管生成。这些发现为了解这些药物在临床环境中的作用提供了重要见解,并提出了治疗缺血性心脏病的新策略。
更新日期:2020-08-11
down
wechat
bug